An official website of the United States government
EGRP Cancer Epidemiology News
July 2026
- 30 Years of Cancer Survivorship Research
- Funding Announcements
- Prize Competitions
- Grants Policy Notices
- Requests for Information
- Research Resources
- Professional Development & Training Opportunities
- NCI & NIH News
30 Years of Cancer Survivorship Research
There were an estimated 18.6 million cancer survivors in 2025, and this number is projected to reach 26 million by 2040. Since 1996, the National Cancer Institute's Office of Cancer Survivorship (OCS) has worked to advance research and care that addresses the physical, psychological, social, and economic effects of cancer and its treatment. Housed within NCI's Division of Cancer Control and Population Sciences (DCCPS), OCS continues to support research, resources, and collaborations that improve the quality and length of survival for people living with and beyond cancer.
This year marks the 30th anniversary of OCS, a major milestone that reflects three decades of progress in survivorship science and deeper understanding of the long-term and late effects of cancer and its treatment.
WATCH: A message from Dr. Gary L. Ellison
Acting Director, Office of Cancer Survivorship
Acting Director, Division of Cancer Control and Population Sciences
NCI encourages investigators to explore the OCS website to view survivorship resources, research tools, survivorship statistics, and information developed to support the many survivors, caregivers, and advocates who are engaged in and dedicated to the continued advancement of survivorship care and science.
Complementing the work of OCS, the Clinical and Translational Epidemiology Branch (CTEB) within DCCPS' Epidemiology and Genomics Research Program stimulates, promotes, and supports cancer epidemiologic research to identify clinical, genomic, and lifestyle factors that improve outcomes for cancer survivors. Notably, CTEB manages the vast majority of NCI-funded, large cancer epidemiology survivor cohort studies, defined as cancer epidemiology survivor cohorts that follow at least 1,000 cancer survivors over time and collect data, with at least one in-person visit, either at baseline or follow-up, on survivorship outcomes. These cohorts were the focus of an article published by CTEB staff in the journal Cancer, Epidemiology, Biomarkers, & Prevention in 2025.
Today, more than 20 large cancer epidemiology survivor cohorts are actively funded by NCI and managed by CTEB. These include ColoCare, the St. Jude Lifetime Cohort, Detroit Research on Cancer Survivors (ROCS), and the Lymphoma Epidemiology of Outcomes (LEO) cohort. More details about these and other NCI-supported cohorts are available on EGRP's webpage on cancer epidemiology cohorts.
Investigators interested in establishing or expanding cohort research may also wish to explore PAR-27-073, Research Opportunities in Cancer Epidemiology Cohort Studies. PAR-27-073 is an open funding opportunity announcement that encourages applications to support research in cancer epidemiology cohort studies that address specific knowledge gaps in cancer etiology and survivorship.
In addition to the large cancer epidemiology survivor cohort studies, CTEB's areas of interest related to survivorship include, but are not limited to, the following:
- Understanding the survivorship needs of people living with advanced and metastatic cancer;
- The effects of newer cancer treatments or treatment regimens (e.g., immunotherapies or targeted therapies) on cancer-related outcomes;
- The use and effects of emerging exposures and lifestyle factors, including cannabis, on cancer-related outcomes; and
- Approaches to enhance cancer genetic counseling and testing for cancer survivors and those at risk.
Investigators are invited to contact CTEB program directors with questions.
Funding Announcements
- RFA-RM-27-014, Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
- RFA-RM-27-015, Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
- RFA-RM-27-011, Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
- RFA-RM-27-012, PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
- RFA-RM-27-013, Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
- PAR-27-071, Discovery of the Genetic Basis of Childhood Cancers and of Congenital Anomalies: Gabriella Miller Kids First Pediatric Research Program (X01, Clinical Trial Not Allowed)
- PA-27-037, Predoctoral to Postdoctoral Transition Award (Parent F99/K00, Clinical Trial Not Allowed)
Prize Competitions
- NCI Office of Data Sharing Impact Prize - submission period ends on October 5, 2026
Grants Policy Notices
- NOT-OD-26-090, Notice of Information: Implementation of HHS Annual SBIR and STTR Application/Proposal Limit
Requests for Information
- NOT-OD-26-086, Proposal to Cap the Number of Simultaneous Research Project Grants per Principal Investigator to Support More Researchers and Maximize Scientific Productivity and Innovation - comments are requested by August 3, 2026
- NOT-OD-26-087, Request for Information on Measuring and Rewarding Scientific Impact - comments are requested by August 19, 2026
- NOT-RM-26-004, NIH Common Fund is Soliciting Ideas for NIH-wide Challenges and Opportunities - comments are requested by September 19, 2026
Research Resources
Professional Development & Training Opportunities
- NCI Cancer Prevention Fellowship Program - applications are due August 6, 2026
- NIH Health and Extreme Weather Scholars Program - applications are due August 16, 2026
NCI & NIH News
- Considerations Before Contacting an NIH Program Officer: Practice Guidance Using Health Disparities Science as a Representative Example
- Declare Your Path to Research Independence Through the NIH F99/K00 Funding Opportunity: Prespectives from NIH Institutes and Centers
- You're Invited: A Conversation on NIH's Unified Funding Strategy
- How Do I Find Contract Solicitations?
- Updates to NIH Fellowship, Training, and Career Development Applications: Referral and Review Highlights
- NIH Director's Statement on the Launch of the Bio Genesis Mission, NIH's Component of the National Genesis Mission
- Reflections on Progress and Partnership at ASCO 2026
Stay Connected
Subscribe for Updates
Subscribe
You can subscribe and unsubscribe at any time by entering your email address and selecting your preferences on the page that follows.
Need Help?
EGRP staff can answer questions on grant funding, policies, and research resources. If you do not know who to contact we will do our best to connect you with someone who can help you.
Email Us(240) 276-6730